Investing.com -- IO Biotech (NASDAQ: IOBT) stock rose 6.1% after announcing topline results from its pivotal Phase 3 trial of Cylembio, an investigational cancer vaccine, in combination with Merck ...

IO Biotech said on Monday its experimental combination cancer vaccine helped slow the disease's progression in a late-stage study, but narrowly missed the main goal as the results did not show ...

IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...

A trend towards improvement in overall survival (OS) was observed in patients treated with Cylembio plus pembrolizumab (OS not yet mature), HR=0.79 (CI 0.57-1.10) Cylembio plus pembrolizumab was well ...

IO Biotech said on Monday its experimental cancer vaccine, in combination with Merck's Keytruda, showed improvement in a late ...

These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...

Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically ...

Just 15% of women live for five years if they have been diagnosed with advanced (stage four) endometrial cancer – a cancer which usually starts in the lining of the womb. The treatment, pembrolizumab, ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has received positive and ...

Health-care company shares rose with the broader rebound in stocks as investors increasingly expect a rate cut from the Federal Reserve.

Thousands of Medicare recipients will face higher costs for expensive cancer drugs following passage of two provisions in the One Big Beautiful Bill Act, signed by President Donald Trump in July, The ...